Eight Presentations at ASM Microbe 2017 Further Highlight the Strong Antifungal Effect and Promising Safety Profile of Lead Anti-Infective Candidate SCY-078
05 juin 2017 08h30 HE
|
SCYNEXIS, Inc.
Potent and broad activity of SCY-078 shown against more than 300 clinical Candida isolates Multiple studies confirm high compatibility of SCY-078 with other antifungals and favorable...
Eight SCY-078 Data Presentations at ASM Microbe 2017 Confirm Potential of SCYNEXIS’ Lead Agent to Combat Serious and Life-threatening Fungal Infections
24 mai 2017 09h05 HE
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., May 24, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often...
Potent in vitro Activity of SCYNEXIS’ SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida auris Further Confirmed in an in vitro Study Conducted by the Centers for Disease Control and Prevention (CDC)
11 mai 2017 08h30 HE
|
SCYNEXIS, Inc.
SCY-078 may provide a therapeutic option for this emerging pathogen classified as a serious global health threat by the CDC Multiple studies confirm SCY-078’s broad spectrum of activity against...
SCYNEXIS Reports First Quarter 2017 Financial Results and Provides Update on IV Formulation Development Status
08 mai 2017 16h20 HE
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., May 08, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often...
Eight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS’ Lead Anti-infective Candidate SCY-078
25 avr. 2017 09h00 HE
|
SCYNEXIS, Inc.
Presentations support SCY-078's potential as a novel treatment for Candida infections including multidrug-resistant strains Favorable safety profile of SCY-078 supported by clinical studies...
SCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented at 27th ECCMID
21 avr. 2017 09h00 HE
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., April 21, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often...
SCYNEXIS to Present SCY-078 Data on Novel Lead Anti-infective Candidate at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
12 avr. 2017 08h30 HE
|
SCYNEXIS, Inc.
Oral presentation of Phase 2 study discusses oral SCY-078 in patients with invasive candidiasis Potent in vitro activity of SCY-078 against multidrug-resistant fungal pathogen Candida auris In vitro...
SCYNEXIS, Inc. to Present at the 16th Annual Needham Healthcare Conference
29 mars 2017 09h05 HE
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., March 29, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a drug development company committed to the development and commercialization of novel anti-infectives to address...
SCYNEXIS Reports Full Year 2016 Financial Results and Provides Company Update
13 mars 2017 16h30 HE
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a drug development company committed to the development and commercialization of novel anti-infectives to address...
SCYNEXIS, Inc. to Present at the 29th Annual ROTH Conference
07 mars 2017 09h05 HE
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the 29th Annual ROTH Conference at the...